Valuation: Becton, Dickinson and Company

Market Cap 42.39B 37.18B 34.43B 31.68B 59.93B 4,057B 61.09B 410B 161B 1,992B 159B 156B 6,880B P/E 2026 *
38.3x
P/E 2027 * 29.6x
Enterprise Value 58.34B 51.17B 47.39B 43.61B 82.48B 5,584B 84.09B 565B 222B 2,742B 219B 214B 9,470B EV / Sales 2026 *
3.04x
EV / Sales 2027 * 2.86x
Free-Float
74.04%
Yield 2026 *
2.5%
Yield 2027 * 2.54%
Manager TitleAgeSince
Chief Executive Officer 53 2020-01-27
Director of Finance/CFO 44 2025-12-04
Compliance Officer - 2023-01-31
Director TitleAgeSince
Director/Board Member 75 2002-09-23
Director/Board Member 71 2010-07-25
Chairman 53 2021-04-27
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-5.43% - - 42.39B
-1.94%-3.68%-30.23%-14.51% 160B
-0.36%+0.61%-7.06%-5.09% 107B
+0.89%+2.54%+3.70%+60.04% 59.56B
+0.35%-0.29%+40.73%+55.54% 52.51B
-1.12%-5.08% - - 34.31B
+1.85%+5.48%-8.42%-43.01% 29.46B
+1.69%+0.58%+58.33%-6.25% 25.41B
+0.49%+1.77%-4.82%-5.11% 21.15B
-0.79%+4.46%-4.51%-18.71% 21B
Average +0.28%+0.39%+5.96%+2.86% 56.76B
Weighted average by Cap. +0.16%-0.66%-4.64%+3.55%

Financials

2026 *2027 *
Net sales 19.21B 16.85B 15.6B 14.36B 27.15B 1,838B 27.68B 186B 72.93B 903B 72.12B 70.54B 3,118B 19.71B 17.29B 16.01B 14.73B 27.87B 1,887B 28.41B 191B 74.85B 926B 74.02B 72.4B 3,200B
Net income 1.12B 986M 914M 841M 1.59B 108B 1.62B 10.89B 4.27B 52.86B 4.22B 4.13B 183B 1.45B 1.27B 1.18B 1.08B 2.05B 139B 2.09B 14.03B 5.5B 68.12B 5.44B 5.32B 235B
Net Debt 15.95B 13.99B 12.96B 11.93B 22.56B 1,527B 23B 154B 60.59B 750B 59.91B 58.6B 2,590B 14.07B 12.34B 11.43B 10.52B 19.9B 1,347B 20.28B 136B 53.44B 661B 52.84B 51.69B 2,284B
Logo Becton, Dickinson and Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical management systems (52.4%): medication delivery systems, pharmaceutical systems, advanced patient monitoring systems, etc.; - interventional medical equipment (23.9%): surgical instruments, urological care products, etc.; - diagnostic materials and clinical research and development tools (23.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, tools for studying genes and culturing cells, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (58.6%), Europe/Middle East/Africa (21.6%), Asia (14.2%) and other (5.6%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
153.83USD
Average target price
176.92USD
Spread / Average Target
+15.01%

Quarterly revenue - Rate of surprise